Fig. 1: Evaluation of an exceptional patient response cohort to CDK4/6i-based therapy. | npj Breast Cancer

Fig. 1: Evaluation of an exceptional patient response cohort to CDK4/6i-based therapy.

From: Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer

Fig. 1: Evaluation of an exceptional patient response cohort to CDK4/6i-based therapy.

a Assessment of progression-free survival (PFS) of patients treated with CDK4/6 inhibitors (CDK4/6i) and classified as short (<6 months; n = 29) or long (>23 months; n = 68) PFS. b GSEA of pretreatment tissue from patients with short PFS compared to patients with long PFS. c PFS of patients treated with CDK4/6i first-line. d Enrichr plots of pre-treatment gene sets upregulated (left) or downregulated (right) in first-line patients with short PFS compared to patients with long PFS. e–g Correlations of cell cycle transcripts with immune-stimulatory (e), immunosuppressive (f), or epithelial and mesenchymal (g) gene expression in pre-treatment tissue of patients with short (top) or long (bottom) PFS. Significance was determined by log rank test (a, c), Fisher’s exact test (b, d) or Spearman correlation (e–g; n ≥ 17 patients/group). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page